Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Primary Endpoint Evaluation of a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Blood (2024) 144 (Supplement 1): 1865.

https://doi.org/10.1182/blood-2024-206556

Published: 2024

Journal Articles

Low Variant Allele Frequency (VAF) TP53 Mutation (mut) Is Not a Poor Prognostic Marker in CLL Patients Treated with Targeted Therapy

Daniel Sungchul Choi, Yue Ren, Svitlana Tyekucheva, Stacey M. Fernandes, Mariia Mikhaleva, Kiyomi Mashima, Rayan Fardoun, Samantha J. Shupe, Stephen Martindale, Matthew S. Davids, Jennifer R. Brown, Inhye E. Ahn

Blood (2024) 144 (Supplement 1): 587.

https://doi.org/10.1182/blood-2024-208951

Published: 2024

Journal Articles

Complex Karyotype, but Not Isolated TP53 mutation, Predicts Overall Survival in Chronic Lymphocytic Leukemia Patients in the Era of Targeted Therapy

Roberta Santos Azevedo, Mariia Mikhaleva, Kiyomi Mashima, Stephen Martindale, Stacey M. Fernandes, Svitlana Tyekucheva, Inhye E. Ahn, Matthew S. Davids, Jennifer R. Brown

Blood (2024) 144 (Supplement 1): 583.

https://doi.org/10.1182/blood-2024-206576

Published: 2024

Journal Articles

A Phase 2 Study of Zanubrutinib and Venetoclax (ZV) in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Inhye E. Ahn, Yue Ren, David C. Fisher, Austin I. Kim, Nancy E. Kaddis, Jon E. Arnason, John P. Winters, III, Sobana Balasubramanian, Heather A. Walker, Victoria Patterson, Stacey M. Fernandes, Svitlana Tyekucheva, Matthew S. Davids, Jennifer R. Brown

Blood (2024) 144 (Supplement 1): 1874.

https://doi.org/10.1182/blood-2024-201668

Published: 2024

Journal Articles

Characteristics and Outcomes of Patients with Double Refractory (DR) or Double Exposed (DE) CLL

Blood (2024) 144 (Supplement 1): 4617.

https://doi.org/10.1182/blood-2024-199577

Published: 2024

Journal Articles

A Phase 2 Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter's Syndrome (RS)

Jennifer L. Crombie, Christine E. Ryan, Yue Ren, Svitlana Tyekucheva, Celeste Carey, Aaron Zou, Samantha Normilus, Josie Montegaard, Jacob D. Soumerai, Shruti Bhandari, Jon E. Arnason, Alvaro J Alencar, Austin I. Kim, Erin M. Parry, Philippe Armand, David C. Fisher, Jennifer R. Brown, Matthew S. Davids

Blood (2024) 144 (Supplement 1): 4628.

https://doi.org/10.1182/blood-2024-199234

Published: 2024

Journal Articles

Investigating the Influence of Germline ATM Variants on Susceptibility to Chronic Lymphocytic Leukemia and Other Malignancies

Roberta Santos Azevedo, Francesca Morelli, Kiyomi Mashima, Rayan Fardoun, Svitlana Tyekucheva, Stacey M Fernandes, Samantha J. Shupe, Marissa Terra, Anisha Patel, Joseph Yu, Jennifer R. Brown

Blood (2023) 142 (Supplement 1): 3266.

https://doi.org/10.1182/blood-2023-180136

Published: 2023

Journal Articles

Characterizing ATM Aberrations in Chronic Lymphocytic Leukemia (CLL): Prognostic Implications and Sensitivity to PARP Inhibition

Kiyomi Mashima, Mariia Mikhaleva, Stacey M Fernandes, Samantha J. Shupe, Svitlana Tyekucheva, Matthew S. Davids, Jennifer R. Brown

Blood (2023) 142 (Supplement 1): 6507.

https://doi.org/10.1182/blood-2023-187406

Published: 2023

Journal Articles

Higher Mutational Burden Is an Independent Predictor of Shorter Time to First Treatment in Untreated Chronic Lymphocytic Leukemia Patients

Mariia Mikhaleva, Svitlana Tyekucheva, Kiyomi Mashima, Stacey M Fernandes, Matthew S Davids, Jennifer R. Brown

Blood (2023) 142 (Supplement 1): 3270.

https://doi.org/10.1182/blood-2023-173738

Published: 2023

Journal Articles

A Phase 2 Study of Acalabrutinib, Umbralisib, and Ublituximab (AU2) in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Inhye E Ahn, Yinglu Zhou, Svitlana Tyekucheva, Hannah Cormier, Stacey M Fernandes, Josie Montegaard, Marykate Kilcommons, Jennifer L Crombie, Reid W. Merryman, Erin M Parry, Philippe Armand, David C Fisher, Caron A Jacobson, Matthew S Davids, Jennifer R. Brown

Blood (2023) 142 (Supplement 1): 1914.

https://doi.org/10.1182/blood-2023-180788

Published: 2023

Journal Articles

Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samples

Blood (2023) 142 (5): 421–433.

https://doi.org/10.1182/blood.2022016600

Published: 2023

Includes: Supplemental data

Journal Articles

Resistance to the Non-Covalent BTK Inhibitor Pirtobrutinib

Blood (2022) 140 (Supplement 1): 6981–6982.

https://doi.org/10.1182/blood-2022-160279

Published: 2022

Journal Articles

Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter's Syndrome (RS)

Christine E. Ryan, Jennifer L. Crombie, Svitlana Tyekucheva, Mikaela M. McDonough, Josie S. Montegaard, Austin I. Kim, Jacob D. Soumerai, Alvaro J. Alencar, Shruti Bhandari, David C. Fisher, Jennifer R. Brown, Matthew S. Davids

Blood (2022) 140 (Supplement 1): 9871–9872.

https://doi.org/10.1182/blood-2022-169986

Published: 2022

Journal Articles

Association of Clonal Hematopoiesis of Indeterminate Potential with Time to First Treatment, Incidence of Richter's Syndrome, and Overall Survival in Patients with Chronic Lymphocytic Leukemia

Abi Vijenthira, Aswin Sekar, Christopher J. Gibson, Stephen P. Martindale, Rayan Fardoun, Svitlana Tyekucheva, Yue Ren, Stacey M. Fernandes, Binyamin A. Knisbacher, Cynthia K. Hahn, Gad Getz, Catherine J. Wu, Matthew S. Davids, Jennifer R. Brown

Blood (2022) 140 (Supplement 1): 9868–9870.

https://doi.org/10.1182/blood-2022-163273

Published: 2022

Journal Articles

Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Blood (2022) 140 (Supplement 1): 837–838.

https://doi.org/10.1182/blood-2022-168003

Published: 2022

Journal Articles

Prevalence of Clonal Hematopoiesis of Indeterminate Potential in Patients with Monoclonal B-Cell Lymphocytosis Compared to Untreated Chronic Lymphocytic Leukemia

Anisha V. Patel, Abirami Vijenthira, Aswin Sekar, Christopher J. Gibson, Stephen P. Martindale, Rayan Fardoun, Svitlana Tyekucheva, Stacey M. Fernandes, Binyamin A. Knisbacher, Cynthia K. Hahn, Gad Getz, Catherine J. Wu, Matthew S. Davids, Jennifer R. Brown

Blood (2022) 140 (Supplement 1): 7038–7040.

https://doi.org/10.1182/blood-2022-162707

Published: 2022

Journal Articles

Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome

Matthew S. Davids, Kerry A. Rogers, Svitlana Tyekucheva, Zixu Wang, Samantha Pazienza, Sarah K. Renner, Josie Montegaard, Udochukwu Ihuoma, Timothy Z. Lehmberg, Erin M. Parry, Catherine J. Wu, Caron A. Jacobson, David C. Fisher, Philip A. Thompson, Jennifer R. Brown

Blood (2022) 139 (5): 686–689.

https://doi.org/10.1182/blood.2021011386

Published: 2022

Includes: Supplemental data

Journal Articles

Longer Term Follow-up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) As Initial Therapy for Younger Patients with Chronic Lymphocytic Leukemia

Blood (2021) 138 (Supplement 1): 640.

https://doi.org/10.1182/blood-2021-146624

Published: 2021

Journal Articles

Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia

Ishwarya Murali, Siddha Kasar, Aishath Naeem, Svitlana Tyekucheva, Jasneet K. Khalsa, Emily M. Thrash, Gilad Itchaki, Dimitri Livitz, Ignaty Leshchiner, Shuai Dong, Stacey M. Fernandes, Gad Getz, Amy Johnson, Jennifer R. Brown

Blood (2021) 138 (1): 44–56.

https://doi.org/10.1182/blood.2020006765

Published: 2021

Includes: Supplemental data

Journal Articles

Updated Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab (AVO) for Frontline Treatment of Chronic Lymphocytic Leukemia (CLL)

Matthew S. Davids, MD, Benjamin L. Lampson, MD PhD, Svitlana Tyekucheva, PhD, Jennifer L. Crombie, MD, Samuel Ng, MD PhD, Austin I. Kim, MD, Matthew Weinstock, MD, Jessica Lowney, Samantha Pazienza, Josie Montegaard, NP, Victoria Patterson, BSN, RN, Caron A. Jacobson, MD, Ann S. LaCasce, MD MSc, Philippe Armand, MD PhD, Jon E. Arnason, MD, David C. Fisher, MD, Jennifer R. Brown, MD PhD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-139864

Published: 2020

NARROW

Primary Endpoint Evaluation of a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Low Variant Allele Frequency (VAF) TP53 Mutation (mut) Is Not a Poor Prognostic Marker in CLL Patients Treated with Targeted Therapy

Complex Karyotype, but Not Isolated TP53 mutation, Predicts Overall Survival in Chronic Lymphocytic Leukemia Patients in the Era of Targeted Therapy

A Phase 2 Study of Zanubrutinib and Venetoclax (ZV) in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Characteristics and Outcomes of Patients with Double Refractory (DR) or Double Exposed (DE) CLL

A Phase 2 Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter's Syndrome (RS)

Investigating the Influence of Germline ATM Variants on Susceptibility to Chronic Lymphocytic Leukemia and Other Malignancies

Characterizing ATM Aberrations in Chronic Lymphocytic Leukemia (CLL): Prognostic Implications and Sensitivity to PARP Inhibition

Higher Mutational Burden Is an Independent Predictor of Shorter Time to First Treatment in Untreated Chronic Lymphocytic Leukemia Patients

A Phase 2 Study of Acalabrutinib, Umbralisib, and Ublituximab (AU2) in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samples

Resistance to the Non-Covalent BTK Inhibitor Pirtobrutinib

Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter's Syndrome (RS)

Association of Clonal Hematopoiesis of Indeterminate Potential with Time to First Treatment, Incidence of Richter's Syndrome, and Overall Survival in Patients with Chronic Lymphocytic Leukemia

Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Prevalence of Clonal Hematopoiesis of Indeterminate Potential in Patients with Monoclonal B-Cell Lymphocytosis Compared to Untreated Chronic Lymphocytic Leukemia

Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome

Longer Term Follow-up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) As Initial Therapy for Younger Patients with Chronic Lymphocytic Leukemia

Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia

Updated Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab (AVO) for Frontline Treatment of Chronic Lymphocytic Leukemia (CLL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only